ONCObind™ Procedure Hemoperfusion Filter
Opportunities & Challenges in Metastatic Cancer
“Metastasis is the hallmark of cancer that is responsible for the greatest number of cancer-related deaths.”1 It is estimated that more than 600,000 patients in the United States will die from cancer in 20222, of which 90% will be from metastatic causes.3
Metastatic cancer lacks effective therapies as it is often resistant to chemotherapy, radiation, and immunotherapy. A higher concentration of circulating tumor cells (CTCs) in blood is associated with unfavorable outcomes in metastatic cancer.4
Circulating Tumor Cell Removal Program
ONCObind Procedure for Circulating Tumor Cell Removal
The ONCObind Procedure Hemoperfusion Filter is designed for the adsorption of circulating tumor cells (CTCs) from blood.
The FDA has granted Investigational Device Exemption (IDE) for the ONCObind Procedure, allowing study in patients suffering from metastatic pancreatic ductal adenocarcinoma (PDAC).
Press Releases
- September 25, 2024
ExThera Announces Completion of Phase I OSCAR I Trial - September 3, 2024
Revolutionary Trial Aims to Transform Pancreatic Cancer Treatment - July 13, 2023
ExThera Medical Announces FDA Approval of IDE Application for Use of the ONCObind Extracorporeal Procedure to Remove Circulating Tumor Cells in Patients with Pancreatic Cancer
| 1. | Fares, J., Fares, M.Y., Khachfe, H.H. et al. Molecular principles of metastasis: a hallmark of cancer revisited. Sig Transduct Target Ther 5, 28 (2020). https://doi.org/10.1038/s41392-020-0134-x |
| 2. | https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/2022-cancer-facts-and-figures.pdf |
| 3. | Guan Xiangming, Cancer metastases: Challenges and opportunities, APSB; 5(5)402-18 |
| 4. | https://www.accessdata.fda.gov/cdrh_docs/pdf7/k071729.pdf |
MM-00019 Rev F